Sarepta Therapeutics (SRPT)

$22.82 +0.98 (4.49%)
Market Cap 2.14B
Revenue (ttm) 1.90B
Net Income (ttm) 235.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 12.37%
Debt to Equity Ratio 0.78
Volume 3,389,500
Avg Vol 5,475,600
Day's Range N/A - N/A
Shares Out 104.79M
Stochastic %K 98%
Beta 0.54
Analysts Sell
Price Target $17.71

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dy...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 274 4000
Address:
215 First Street, Suite 415, Cambridge, United States
GoldenLairTrading
GoldenLairTrading Dec. 5 at 12:02 AM
SNSE IS SQUEEZING!!! $RUM $TGL $AMGN $APLT $SRPT W
0 · Reply
Thaigrlsrk
Thaigrlsrk Dec. 4 at 10:41 PM
$SRPT You have to wonder if EMA has ever contacted any DMD researcher about Elevidys? Or any patient for that matter.
0 · Reply
Iightning
Iightning Dec. 4 at 10:31 PM
1ightning® Premium Options Alert (Actionable) Ticker: $SRPT Contract: Dec 19 $23C Entry: 1.40 Exit: 2.07 Return: +47.86% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Golden_Bullys
Golden_Bullys Dec. 4 at 10:23 PM
SNSE will SQUEEZE DON'T OVERLOOK IT!! $CHPT $SRPT $PSKY $STZ $GSAT 00
0 · Reply
TheHacDay
TheHacDay Dec. 4 at 10:23 PM
$SRPT l should have kept my SRPT shares. I got shaken out when it dropped unnecessarily to 15.90 2 weeks ago. I feel so stupid. I’ve come to love this stock!
1 · Reply
Thaigrlsrk
Thaigrlsrk Dec. 4 at 10:14 PM
$SRPT Based on a study I saw and what LRK/DI has said on calls , I think that eventually we may see all kids get Sirolimus because of an increase in Elevidys effectiveness when using it.
1 · Reply
drbrain00
drbrain00 Dec. 4 at 10:13 PM
$SRPT I hope all these folks super excited about Capricor realize that the total addressable market for deramiocel is a fraction of Elevidys. It’s just the nonambulant older kids and there is a good chance these two are complementary drugs. Capricor stock is on a tear but reality will soon settle in. Sarepta will get competition from next generation drugs from Regenxbio , Avidity and Dyne but they will also have their RNA drug from Arrowhead by then which is best in class
1 · Reply
Thaigrlsrk
Thaigrlsrk Dec. 4 at 10:13 PM
$SRPT Here's what i think about capr 1) it is not a competitor and will take zero patients from Sarepta and i base that on what Dr. McDonald said on the CAPR call. Capr is a good bet for increase in SP.
0 · Reply
Plowmaster
Plowmaster Dec. 4 at 10:07 PM
$SRPT When did this become SRPT vs CAPR? Comparing an approved, scaling gene therapy to Phase 2 MRI signals is like calling a scrimmage a championship game.
1 · Reply
goldengatesings2
goldengatesings2 Dec. 4 at 9:33 PM
$CAPR $SRPT Cardiac benefit is the biggest danger to Elevidys DMD patients die of cardiomyopathy. No Phase 3 Elevidys dataset shows a statistically significant cardiac protection effect. HOPE-3 does. This immediately positions Deramiocel as a cardiac drug that is life-extending and supported by MRI-based cardiac endpoints which regulators and clinicians value highly. If a therapy protects the heart, it becomes standard of care, even if gene therapy remains an early-age option. This is a serious strategic blow for Sarepta.
6 · Reply
Latest News on SRPT
Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk

Nov 25, 2025, 12:07 PM EST - 9 days ago

Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Nov 25, 2025, 8:57 AM EST - 9 days ago

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

Nov 24, 2025, 7:30 AM EST - 10 days ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

ARWR

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Nov 24, 2025, 7:30 AM EST - 10 days ago

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

2 Beaten-Down Stocks to Avoid Right Now

Nov 15, 2025, 9:35 AM EST - 19 days ago

2 Beaten-Down Stocks to Avoid Right Now

NTLA

Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Nov 14, 2025, 5:48 PM EST - 20 days ago

Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Nov 14, 2025, 2:54 PM EST - 20 days ago

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Nov 14, 2025, 2:08 PM EST - 20 days ago

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026

Nov 4, 2025, 1:39 PM EST - 4 weeks ago

Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Nov 4, 2025, 12:33 PM EST - 4 weeks ago

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It

Nov 4, 2025, 12:11 PM EST - 4 weeks ago

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It

Sarepta Therapeutics shares plunge after disappointing trial data

Nov 4, 2025, 9:55 AM EST - 4 weeks ago

Sarepta Therapeutics shares plunge after disappointing trial data

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Nov 4, 2025, 6:20 AM EST - 4 weeks ago

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Sarepta Therapeutics, Inc. (SRPT) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 5:36 AM EST - 4 weeks ago

Sarepta Therapeutics, Inc. (SRPT) Q3 2025 Earnings Call Transcript

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Nov 4, 2025, 4:27 AM EST - 4 weeks ago

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Nov 3, 2025, 6:26 PM EST - 4 weeks ago

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:24 PM EST - 4 weeks ago

Sarepta's Duchenne gene therapy misses main goal in study

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Nov 3, 2025, 4:05 PM EST - 4 weeks ago

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Oct 27, 2025, 4:05 PM EDT - 5 weeks ago

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

Oct 23, 2025, 6:46 AM EDT - 6 weeks ago

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

BLSH DASH FLY IREN NEM OPEN QS

Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline

Oct 10, 2025, 11:49 AM EDT - 7 weeks ago

Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline

What's Going On Sarepta Stock On Wednesday?

Oct 8, 2025, 11:19 AM EDT - 2 months ago

What's Going On Sarepta Stock On Wednesday?

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Oct 3, 2025, 8:30 AM EDT - 2 months ago

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 30, 2025, 6:00 PM EDT - 2 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

Sep 5, 2025, 9:00 AM EDT - 3 months ago

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 3 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN IONS MRNA

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

Aug 25, 2025, 3:11 AM EDT - 3 months ago

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)

Aug 23, 2025, 7:08 AM EDT - 3 months ago

SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)

Sarepta Therapeutics: A Strong Opportunity Amidst The Panic

Aug 22, 2025, 12:12 PM EDT - 3 months ago

Sarepta Therapeutics: A Strong Opportunity Amidst The Panic

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Aug 22, 2025, 9:50 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

Aug 21, 2025, 7:00 AM EDT - 3 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

SRPT Update: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline

Aug 20, 2025, 3:30 PM EDT - 3 months ago

SRPT Update: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline

Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman

Aug 18, 2025, 12:01 PM EDT - 3 months ago

Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Aug 14, 2025, 12:14 PM EDT - 4 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment

Aug 13, 2025, 4:12 PM EDT - 4 months ago

Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment

SAREPTA STOCK: Lose Money on Your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investment? Contact BFA Law before the August 25 Legal Deadline

Aug 13, 2025, 8:33 AM EDT - 4 months ago

SAREPTA STOCK: Lose Money on Your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investment? Contact BFA Law before the August 25 Legal Deadline

SRPT COURT NOTICE: Sarepta Therapeutics Investors may have been Affected by Fraud -- Contact BFA Law before August 25 if You Suffered Losses (NASDAQ:SRPT)

Aug 11, 2025, 8:18 AM EDT - 4 months ago

SRPT COURT NOTICE: Sarepta Therapeutics Investors may have been Affected by Fraud -- Contact BFA Law before August 25 if You Suffered Losses (NASDAQ:SRPT)

These Stocks Are Moving the Most Today: Coinbase, MicroStrategy, Sarepta, Nvidia, AMD, and More

Aug 11, 2025, 5:26 AM EDT - 4 months ago

These Stocks Are Moving the Most Today: Coinbase, MicroStrategy, Sarepta, Nvidia, AMD, and More

AMD COIN MSTR NVDA

Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments

Aug 6, 2025, 4:05 PM EDT - 4 months ago

Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments

Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results

Jul 31, 2025, 8:48 AM EDT - 4 months ago

Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPT

Jul 31, 2025, 8:45 AM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPT

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 4 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR CABA NGNE NTLA QURE RCKT

GoldenLairTrading
GoldenLairTrading Dec. 5 at 12:02 AM
SNSE IS SQUEEZING!!! $RUM $TGL $AMGN $APLT $SRPT W
0 · Reply
Thaigrlsrk
Thaigrlsrk Dec. 4 at 10:41 PM
$SRPT You have to wonder if EMA has ever contacted any DMD researcher about Elevidys? Or any patient for that matter.
0 · Reply
Iightning
Iightning Dec. 4 at 10:31 PM
1ightning® Premium Options Alert (Actionable) Ticker: $SRPT Contract: Dec 19 $23C Entry: 1.40 Exit: 2.07 Return: +47.86% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Golden_Bullys
Golden_Bullys Dec. 4 at 10:23 PM
SNSE will SQUEEZE DON'T OVERLOOK IT!! $CHPT $SRPT $PSKY $STZ $GSAT 00
0 · Reply
TheHacDay
TheHacDay Dec. 4 at 10:23 PM
$SRPT l should have kept my SRPT shares. I got shaken out when it dropped unnecessarily to 15.90 2 weeks ago. I feel so stupid. I’ve come to love this stock!
1 · Reply
Thaigrlsrk
Thaigrlsrk Dec. 4 at 10:14 PM
$SRPT Based on a study I saw and what LRK/DI has said on calls , I think that eventually we may see all kids get Sirolimus because of an increase in Elevidys effectiveness when using it.
1 · Reply
drbrain00
drbrain00 Dec. 4 at 10:13 PM
$SRPT I hope all these folks super excited about Capricor realize that the total addressable market for deramiocel is a fraction of Elevidys. It’s just the nonambulant older kids and there is a good chance these two are complementary drugs. Capricor stock is on a tear but reality will soon settle in. Sarepta will get competition from next generation drugs from Regenxbio , Avidity and Dyne but they will also have their RNA drug from Arrowhead by then which is best in class
1 · Reply
Thaigrlsrk
Thaigrlsrk Dec. 4 at 10:13 PM
$SRPT Here's what i think about capr 1) it is not a competitor and will take zero patients from Sarepta and i base that on what Dr. McDonald said on the CAPR call. Capr is a good bet for increase in SP.
0 · Reply
Plowmaster
Plowmaster Dec. 4 at 10:07 PM
$SRPT When did this become SRPT vs CAPR? Comparing an approved, scaling gene therapy to Phase 2 MRI signals is like calling a scrimmage a championship game.
1 · Reply
goldengatesings2
goldengatesings2 Dec. 4 at 9:33 PM
$CAPR $SRPT Cardiac benefit is the biggest danger to Elevidys DMD patients die of cardiomyopathy. No Phase 3 Elevidys dataset shows a statistically significant cardiac protection effect. HOPE-3 does. This immediately positions Deramiocel as a cardiac drug that is life-extending and supported by MRI-based cardiac endpoints which regulators and clinicians value highly. If a therapy protects the heart, it becomes standard of care, even if gene therapy remains an early-age option. This is a serious strategic blow for Sarepta.
6 · Reply
__GoldenSteers
__GoldenSteers Dec. 4 at 9:05 PM
SNSE will SQUEEZE DON'T OVERLOOK IT!! $BGLC $FSLY $SRPT $BFLY Half
0 · Reply
Gunnar_Bunker
Gunnar_Bunker Dec. 4 at 7:55 PM
$SRPT
0 · Reply
goldengatesings2
goldengatesings2 Dec. 4 at 7:04 PM
$SRPT $CAPR The deeper I look into HOPE-3 results , I don’t think Sarepta non-ambulant therapy is going to be approved even with sirolimus. And their current ambulant therapy may also get challenged by Capricorn down the road. Switched entire investment in $SRPT to $CAPR.
7 · Reply
Gunnar_Bunker
Gunnar_Bunker Dec. 4 at 6:52 PM
$SRPT this will be 70$ atleast
0 · Reply
Neubaufahrzeug
Neubaufahrzeug Dec. 4 at 6:17 PM
$SRPT unloading half for now.
0 · Reply
WeAreKangz
WeAreKangz Dec. 4 at 6:14 PM
$SRPT gap filled today from the earnings drop. Uncharted territory here for the short term
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Dec. 4 at 5:37 PM
$SRPT just looking at the chart, if we hadn't had that crazy reaction to the near meaningless pmo results this would be a $35 name
0 · Reply
epet3
epet3 Dec. 4 at 5:36 PM
$SRPT WERE JUST GETTING STARTED!!!
0 · Reply
StackTroder
StackTroder Dec. 4 at 5:35 PM
$SRPT Yes it's genius from a risk perspective - multiple shots on goal!
0 · Reply
TradeOrGoHome
TradeOrGoHome Dec. 4 at 5:34 PM
$SRPT nice! Holding all of my shares until $80, not selling a single share.
1 · Reply
Moneyindabanknow
Moneyindabanknow Dec. 4 at 5:30 PM
$SRPT this is about to bust up fast
0 · Reply
patcher337
patcher337 Dec. 4 at 5:28 PM
$SRPT will need to see how we will react when it get close to $24. there is quite a bit of sell pressure there. I am guessing we are not getting through on the first try. We might consolidate between $20 to $24 range as long as we have no news... Like no news. Let the company do its work and execute this quarter.
0 · Reply